Eligibility. Applicants must meet the following criteria to qualify for a YIA: Be a physician (MD, DO, or international equivalent) working in any country and currently in the last two years of their ...

American Society of Clinical Oncology (ASCO) and Egyptian Cancer Society (ECS) leaders signed a Memorandum of Understanding (MOU) on June 2, 2025, during ASCO’s 61st Annual Meeting. The MOU formally ...

While federal prior authorization reform legislation has yet to make it over the finish line and be enacted into law, state governments continue to pass legislation to mitigate the burdensome ...

Decentralized clinical trial elements can be safely adopted as permanent fixtures without substantial reductions in data quality or increased risk to research participants, according to a new study in ...

The American Society of Clinical Oncology (ASCO) has been notified of a recent safety notice for the drug Jubbonti (denosumab-bbdz) under the Food and Drug Administration’s Risk Evaluation and ...

The Association for Clinical Oncology (ASCO) is outlining key priorities for the next generation of biomedical innovation policy in response to “A Roadmap for 21st Century Cures,” a white paper ...

CHICAGO — Results from the international phase 3 AMPLITUDE clinical trial found that adding niraparib to abiraterone acetate (AKEEGA™) plus prednisone (AAP) can help slow cancer growth for people with ...

CHICAGO — Results from the phase 3 DESTINY-Breast09 clinical trial found that the combination of trastuzumab deruxtecan (Enhertu®) with pertuzumab (Perjeta®) can delay cancer growth for longer than ...

CHICAGO — New study results show that a structured exercise program following surgery and adjuvant chemotherapy reduced the risk of recurrent or new cancer and increased survival for patients with ...

Focus: Previously untreated, resectable gastric cancer (GC) and gastroesophageal junction cancer (GEJC) Population: 948 patients: Main Takeaway: Perioperative treatment with durvalumab (Imfinzi) and ...

CHICAGO — Results from the phase 3 SERENA-6 clinical trial found that switching to treatment with camizestrant if an ESR1 mutation is detected during first-line treatment can help slow cancer growth ...

ASCO Perspective Quote “This early but promising observational study suggests a powerful synergy: patients with stage III colon cancer who embraced anti-inflammatory foods and exercised regularly ...